No Data
No Data
No Data
No Data
No Data
Hepion Ends Phase 2 Study for NASH Drug Due to Cash Restraints
Seeking AlphaApr 19 17:10 ET
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Shares of PriceSmart, Inc. (NASDAQ:PSMT) rose sharply in today's pre-market trading as the company posted better-than-expected earnings for its second quarter. The company reported quarterly earnings
BenzingaApr 10 08:12 ET
Madrigal Announces US Launch of NASH/MASH Drug Rezdiffra
Seeking AlphaApr 9 10:03 ET
Why Agenus Shares Are Trading Lower By Around 17%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Agenus Inc. (NASDAQ:AGEN) fell sharply during Monday's session. Agenus disclosed a 1-for-20 reverse stock split of common stock. Agenus Inc. (NASDAQ:AGEN) declined 17% to $0.4181 on Monday.
BenzingaApr 8 13:10 ET
Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares rose sharply during today's pre-market trading after the company presented new data from CLEAR outcomes at ACC.24 highlighting value of NEX
BenzingaApr 8 05:15 ET
Galmed Pharmaceuticals Ltd. (GLMD) Surges After Hours: An Unexpected Rally
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) concluded its Friday's trading session with a modest 2.8% gain, leaving investors to be cautiously optimistic. However, the post-closing activity took an unforeseen turn, with GLMD experiencing a remarkable 15% surge in after-hours trading. During the typically quieter after-hours session, GLMD's stock surged, capturing investors' attention. Trading volume spiked to ...
Stocks TelegraphApr 8 03:35 ET
TrytosaveabitOP :
Inventiva said the Phase 2 proof-of-concept study met its primary endpoint with an absolute reduction of HbA1c of 1.14% to 1.59% in patients treated with lanifibranor or in combination with empagliflozin at week 24 versus an increase of 0.26% in the placebo arm.
Patients treated with the combination also were able to maintain a stable weight throughout the 24 weeks of the study.
No Data
No Data